Save time and get answers to complex questions with AI chat
Zemdri plazomicin nce gain exclusivity 2028 patent 2031?When is the expected fda decision date for apotex's ruxolitinib resubmission?How does iron rich food intake impact lipitor's efficacy?Patent expiry trametinib?Combivent inhaler hfc 152a patents?
See the DrugPatentWatch profile for Erleada
Erleada is the brand name for the drug apalutamide.
Apalutamide is used for certain cases of prostate cancer, including non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (depending on the specific indication and approval/labeling).
If a generic is available, it would generally be sold under the generic name apalutamide (not “Erleada”). Exact availability depends on the market and regulatory status.
For the latest on generic-entry status and patent information tied to Erleada/apalutamide, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/ Sources: 1. https://www.drugpatentwatch.com/
Other Questions About Erleada :